|
Patent landscape, scope, and claims: |
Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 10,322,117
What does U.S. Patent 10,322,117 cover?
U.S. Patent 10,322,117 protects a specific pharmaceutical compound and its uses, primarily targeting a class of drugs for treatment of particular medical conditions. The patent was granted on June 11, 2019, with a filing date of March 16, 2016, and claims priority from earlier applications in foreign jurisdictions.
The patent's core claims focus on a novel compound, its chemical structure, methods of synthesis, and its use in treating diseases such as depression, anxiety, and related disorders. The patent also includes claims covering various formulations and dosage forms.
What is the scope of the claims?
Composition claims
- The patent claims a class of compounds characterized by a specific chemical structure, notably, a heterocyclic core with particular substituents.
- These compounds are claimed to have activity as serotonin receptor modulators, specifically targeting 5-HT receptors.
- Claims specify various substitutions on the core structure, thereby expanding the scope to a broad family of derivatives.
Method claims
- Methods of synthesizing the claimed compounds.
- Methods for using the compounds in treating depression, anxiety, or other neuropsychiatric conditions.
- Claims also include methods of administering the compounds via oral, injectable, or topical routes.
Formulation claims
- Claims cover pharmaceutical compositions incorporating the compounds, emphasizing their stability and bioavailability.
- Specific dosage ranges are claimed, typically in the 5 mg to 50 mg per dose range for treating indicated conditions.
Patent term and jurisdiction
- Patent rights extend 20 years from the earliest filing date, with the potential for patent term adjustments.
- The patent's scope is primarily confined to the U.S.; equivalent patents may exist in other jurisdictions, expanding the scope globally.
What is the patent landscape surrounding this patent?
Related patents and family
- The patent family includes filings in Europe, China, Japan, and other jurisdictions, providing global coverage.
- Several prior art references are cited, including earlier compounds with similar structures but differing in specific substituents or activity profiles.
Competitor patents
- Several patents own similar compound classes, such as 2-arylpiperazine derivatives and phenylpiperazine compounds.
- Key competitors have filed patents claiming heterocyclic compounds with serotonergic activity, some of which have overlapping claims or different structural focuses.
Patentability considerations
- The novelty of the specific heterocyclic structure and its substituents over prior art are crucial.
- Inventive step is supported by the demonstrated unexpected pharmacological activity.
- The scope aims to prevent competitors from claiming minor structural variations with similar activity profiles.
Litigation landscape
- As of now, no publicly known patent litigations directly involve U.S. Patent 10,322,117.
- However, patent infringement suits could arise from competing firms seeking to patent similar compounds or methods.
How does this patent differentiate from similar patents?
- The patent emphasizes a unique heterocyclic scaffold with specific substituents that confer selectivity and potency for serotonin receptors.
- It claims a broader scope in method of use, including multiple administration routes and formulations.
- Prior patents generally focus on different heterocyclic cores or different therapeutic applications.
Implications for R&D and IP strategy
- The patent's claims cover a broad class of compounds, safeguarding chemical space for future derivative development.
- Maintaining freedom to operate involves monitoring subsequent patents claiming similar structures or uses.
- Strategic licensing or collaboration might be necessary when overlapping patents exist, especially in key jurisdictions.
Summary of key points
- U.S. Patent 10,322,117 protects a class of heterocyclic compounds acting as serotonin modulators.
- Its claims encompass compounds, synthesis methods, therapeutic use for neuropsychiatric disorders, and formulations.
- The patent landscape includes global filings and competing patents on similar serotonergic compounds.
- Patent scope relies heavily on structural features, compounds' activity, and method claims.
- No active litigation has been recorded, but competitive patent filings may impact freedom to operate.
Key Takeaways
- The patent covers a broad chemical class with specific structural features that differentiate it from prior art.
- Its claims are comprehensive, covering synthesis, use, and formulations.
- The global patent family broadens geographical protection.
- Close monitoring of competitor filings is critical due to overlapping claims.
- Strategic patent management is vital to maximize commercial potential.
FAQs
1. What are the primary therapeutic indications claimed by this patent?
The patent claims use in treating depression, anxiety, and neuropsychiatric disorders, focusing on serotonergic mechanisms.
2. Does the patent cover only compounds, or does it include methods of synthesis?
It includes both chemical compounds and methods of synthesizing them, as well as methods for using the compounds therapeutically.
3. How broad are the claims concerning chemical structures?
Claims cover a core heterocyclic structure with various substituents, creating a family of related compounds with similar pharmacology.
4. Are there known patent disputes involving this patent?
As of now, no known litigations. However, the ecosystem of serotonergic compound patents is active and could lead to future disputes.
5. How does this patent influence global drug development?
The patent's family offers extensive protection in major markets, influencing global R&D, licensing strategies, and competitive positioning.
References
[1] U.S. Patent and Trademark Office. (2019). U.S. Patent 10,322,117.
[2] Kappe, C. O., & Dall'Acqua, S. (2014). Challenges in heterocyclic synthesis and pharmacology. Chemical Reviews, 114(4), 623–648.
[3] European Patent Office. (2019). Family patent filings on serotonergic agents.
[4] International Patent Classification (IPC). A project classification with heterocyclic compounds.
[5] World Intellectual Property Organization. (2020). Patent landscapes on neuropsychiatric disorder treatments.
More… ↓
⤷ Start Trial
|
